Ovarian Cancer | Specialty

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

FDA Grants Priority Review to Maintenance Rucaparib for Ovarian Cancer

December 6th 2017

The FDA has granted a priority review to a supplemental new drug application for rucaparib (Rubraca) for use as a maintenance treatment for patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.

Time Between Neoadjuvant and Adjuvant Chemo Impacts OS in Ovarian Cancer

December 5th 2017

Patients with ovarian cancer who begin postoperative adjuvant chemotherapy within 42 days of ending neoadjuvant chemotherapy have superior survival compared to those who initiate therapy after that point.

Dr. Sabbatini on Novel Approaches With IP Therapy For Ovarian Cancer

November 30th 2017

Paul Sabbatini, MD, deputy physician-in-chief for clinical research, Memorial Sloan Kettering Cancer Center, discusses novel approaches for IP therapy for patients with ovarian cancer.

Dr. Dottino on Targeted Therapies in Ovarian Cancer

November 28th 2017

Peter R. Dottino, MD, professor of obstetrics, gynecology and reproductive science, Mount Sinai Hospital, discusses targeted therapies for patients with ovarian cancer.

Niraparib Approved in Europe for Ovarian Cancer

November 23rd 2017

The European Commission has approved niraparib as a maintenance therapy for women with platinum-sensitive relapsed high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.

Expert Discusses Promise of Checkpoint Inhibitors in Ovarian Cancer

November 21st 2017

Jonathan Ledermann, MD, discusses the promise of immunotherapy in ovarian cancer and emphasized the importance of participation in clinical trials.

Dr. Leitao on the Benefits of Surgery in Ovarian Cancer

November 21st 2017

Mario M. Leitao Jr, MD, FACOG, FACS, fellowship director, gynecology service, director, Minimal Access and Robotic Surgery Program, Department of Surgery, Memorial Sloan Kettering Cancer Center, discusses the importance of surgery for patients with ovarian cancer.

The Future Role of PARP Inhibition in Ovarian Cancer

November 20th 2017

Combinations With PARP Inhibitors for Ovarian Cancer

November 20th 2017

Ovarian Cancer: Selecting an Appropriate PARP Inhibitor

November 20th 2017

Ovarian Cancer: Treating Through Multiple Progressions

November 20th 2017

Ovarian Cancer: Comparisons Between PARP Inhibitors

November 20th 2017

PARP Inhibitors's Role as Maintenance Therapy in EOC

November 20th 2017

Ovarian Cancer: Optimizing Treatment With Niraparib

November 20th 2017

Treating Ovarian Cancer With Niraparib: The NOVA Trial

November 20th 2017

Platinum-Sensitive Relapsed Ovarian Cancer: Rucaparib

November 20th 2017

Value of Olaparib in BRCA-Mutated Advanced Ovarian Cancer

November 20th 2017

PARP Inhibitors' Impact on Advanced Ovarian Cancer

November 20th 2017

Ovarian Cancer: Considerations for Molecular Testing

November 20th 2017

Ovarian Cancer: Testing for Mutations

November 20th 2017